David Nittner
Overview
Explore the profile of David Nittner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
More S, Bonnereau J, Wouters D, Spotbeen X, Karras P, Rizzollo F, et al.
Sci Adv
. 2024 Oct;
10(42):eadp6164.
PMID: 39413195
A major therapeutic barrier in melanoma is the coexistence of diverse cellular states marked by distinct metabolic traits. Transitioning from a proliferative to an invasive melanoma phenotype is coupled with...
2.
Talebi A, de Laat V, Spotbeen X, Dehairs J, Rambow F, Rogiers A, et al.
J Exp Clin Cancer Res
. 2023 Apr;
42(1):92.
PMID: 37072838
Background: One of the key limitations of targeted cancer therapies is the rapid onset of therapy resistance. Taking BRAF-mutant melanoma as paradigm, we previously identified the lipogenic regulator SREBP-1 as...
3.
Heylen E, Verstraete P, Van Aerschot L, Geeraerts S, Venken T, Timcheva K, et al.
Br J Cancer
. 2023 Mar;
128(10):1862-1878.
PMID: 36932191
Background: One-third of cancers activate endogenous synthesis of serine/glycine, and can become addicted to this pathway to sustain proliferation and survival. Mechanisms driving this metabolic rewiring remain largely unknown. Methods:...
4.
Vandersmissen C, Prieto C, Gielen O, Jacobs K, Nittner D, Maertens J, et al.
Haematologica
. 2023 Jan;
108(9):2507-2512.
PMID: 36700404
No abstract available.
5.
Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M, et al.
Cancer Cell
. 2023 Jan;
41(1):226.
PMID: 36626867
No abstract available.
6.
Izci M, Maksoudian C, Goncalves F, Aversa L, Salembier R, Sargsian A, et al.
J Nanobiotechnology
. 2022 Dec;
20(1):518.
PMID: 36494816
Nanoparticle (NP) delivery to solid tumors remains an actively studied field, where several recent studies have shed new insights into the underlying mechanisms and the still overall poor efficacy. In...
7.
Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M, et al.
Cancer Cell
. 2022 Nov;
40(12):1600-1618.e10.
PMID: 36423635
The lack of T cell infiltrates is a major obstacle to effective immunotherapy in cancer. Conversely, the formation of tumor-associated tertiary-lymphoid-like structures (TA-TLLSs), which are the local site of humoral...
8.
Rossi M, Altea-Manzano P, Demicco M, Doglioni G, Bornes L, Fukano M, et al.
Nature
. 2022 Aug;
609(7927):E8.
PMID: 36042336
No abstract available.
9.
Vanden Bempt M, Debackere K, Demeyer S, Van Thillo Q, Meeuws N, Prieto C, et al.
Blood
. 2022 Aug;
140(23):2463-2476.
PMID: 35960849
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological cancers arising from the malignant transformation of mature T cells. In a cohort of 28 PTCL cases, we identified recurrent...
10.
Rossi M, Altea-Manzano P, Demicco M, Doglioni G, Bornes L, Fukano M, et al.
Nature
. 2022 May;
605(7911):747-753.
PMID: 35585241
Cancer metastasis requires the transient activation of cellular programs enabling dissemination and seeding in distant organs. Genetic, transcriptional and translational heterogeneity contributes to this dynamic process. Metabolic heterogeneity has also...